Cerbios showcasing CHO-derived r-UK at CPhI Madrid
Press Release | Cerbios-Pharma SA
AUGUST 13, 2015
Barbengo / Lugano, Switzerland:- The Swiss-based high-tech Cerbios-Pharma SA (Cerbios) will be a participant at the landmark CPhI Worldwide event in Madrid in October.
Cerbios will use CPHI to present details of its breakthrough recombinant-Urokinase (r-UK) and services in monoclonal antibody and antibody drug conjugates (ADC) area.
The Cerbios team at CPhI will also include CEO Gabriel Haering, Chief Commercial Officer Andrea Tam, Marketing and Sales Director Annalisa Miracca. All will be on the Cerbios-Pharma exhibition stand at Booth 7K60 in Hall 7 at IFEMA Madrid.
Cerbios will host a networking “Tapas event” at the Piazza Ticino Booth on the evening of Day one of the event (October 13, from 5 pm).
High-tech r-UK platform
Cerbios have regularly attended CPhI Europe for more than a decade.
“Once again, we will be reaching out to pharmaceutical companies working in biotechnology and highly potent small molecules areas,” said Mr. Tam. “We will be showing how they can use Cerbios-Pharma to access highly advanced technology platforms.”
“In particular, we can offer partnership opportunities to develop our CHO-derived r-UK as a characterized molecule with a novel manufacturing process. We can provide direct access to a molecule known to be an effective thrombolytic along with a patent-protected and validated manufacturing process, established cGMP manufacturing capabilities, pre-clinical and clinical protocol outlines and worldwide marketing rights for a therapy that, once approved, will enjoy a very substantial market,” said Mr. Tam.
Cerbios-Pharma SA is a Swiss company founded in 1994 by the merger three pre existing companies under the same ownership. It specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of small molecules (Chemical Division) and in the production of biopharmaceuticals (Biological Division).
Using its experience and capabilities Cerbios has developed a recombinant form of Urokinase, using CHO cell lines. Because this form of r-UK is not extracted from human urine or kidney cells, it avoids previous problems of inconsistencies, potential transfer of adventitious agents or viral contamination.
Cerbios’ r-UK system is based on a proprietary cGMP mammalian cell culture platform using a state of the art defined medium, serum free and without addition of growth factors or antibiotics.
This leads to a product with a high safety profile.
About CPhI Worldwide
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.
Now in its 26th year, the 2015 event is a three-day event opening October 13 at IFEMA, Feria de Madrid, Spain. It will host more than 36,000 delegates from 150 countries along with 2,500 exhibitor companies.
The CPhl Worldwide show is being held alongside three other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events.
The Pre-Connect Conference on October 12 brings together senior representatives and key stakeholders from all segments of the industry for a series of market-led educational modules on the latest trends and topics with networking and partnering opportunities.
The CPhI Pharma Awards, presented on the first evening of the conference, honor innovative companies and leaders. The previous three categories (formulation, process development and packaging) have now been expanded to eight awards, now additionally honouring best innovations in biologic drug development and manufacturing, supply chain & logistic management, manufacturing technology, APIs and excipients, as well as CEO of the Year.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: http://www.cphi.com/europe/home
Mara Camillo, Business Development Manager, Cerbios-Pharma SA
Tel: +41 91 9856556
Click on Cerbios Biological showcasing CHO-derived r-UK at CPhI Madrid for more information.
Click on Cerbios-Pharma to contact the company directly.